Johnson & Johnson Stock Forecast for 2022 - 2025 - 2030
Updated on 05/19/2022
Johnson & Johnson's most recent price target of $185.00 for 2022 was provided by sixteen renowned analysts over the past few months, with an average prediction of $185.00. If this prediction is correct, Johnson & Johnson's stock could rise by 5.41 percent from its current trading price. The potential increase for the stock is $185.00 per share, with a possible range of $167.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.
5.41% Upside
Johnson & Johnson Price Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Price has seen major growth over the last four years, jumping from $128.63 to $172.68 – an increase of 34.25%. In the next year, analysts predict that Price will reach an unimpressive $180.78 – an increase of 4.69%. For the next nine years, the forecast is for Price to grow by 32.65%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
5
|
$152.43 | $152.52 | 10.21% | 19 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
7
|
$112.74 | $141.24 | 24.18% | 19 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£102.44 | £136.08 | 42.07% | 13 |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
8
|
$77.02 | $76.69 | 1.27% | 16 |
| AMGN Stock Forecast | Amgen | Hold |
8
|
$243.96 | $246.46 | 1.45% | 13 |
Johnson & Johnson Revenue Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Revenue has seen major growth over the last four years, jumping from $76450.00 to $93775.00 – an increase of 22.66%. In the next year, analysts predict that Revenue will reach an unimpressive $96295.55 – an increase of 2.69%. For the next nine years, the forecast is for Revenue to grow by 12.28%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$251.10 | $270.20 | 13.5% | 3 |
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.80€ | 67.79€ | 19.12% | 14 |
| CL Stock Forecast | Colgate-Palmolive | Hold |
4
|
$75.71 | $84.90 | 8.31% | 9 |
Johnson & Johnson Dividend per Share Forecast for 2022 - 2025 - 2030
Over the last four years, Johnson & Johnson's DPS has increased by 26.2%, going from $3.32 to $4.19. In the next year, analysts are expecting a small increase in EPS, predicting it will reach $4.45 – an increase of 6.21%. The 2030 forecast is for DPS to reach $5.75 or grow by 37.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
4
|
$40.23 | $49.85 | 24.29% | 23 |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
3
|
¥3.79k | ¥0.00 | 18.73% | 0 |
| BAS Stock Forecast | BASF | Outperform |
5
|
49.86€ | 78.27€ | 28.36% | 16 |
Johnson & Johnson Free Cash Flow Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Free Cash Flow has increased by 11.14% in the last four years, going from $17777.00 to $19758.00. In the next year, analysts expect Free Cash Flow to reach a reasonable $23174.60 – an increase of 17.29%. For the next nine years, the forecast is for Free Cash Flow to grow by 47.66%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BNTX Stock Forecast | BioNTech | Hold |
0
|
$284.21 | $0.00 | -11.75% | 3 |
| ALC Stock Forecast | Alcon | Outperform |
0
|
CHF79.00 | CHF0.00 | 15.3% | 14 |
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$72.12 | $92.47 | 24.79% | 3 |
Johnson & Johnson Net Income Forecast for 2022 - 2025 - 2030
In the past four years, Johnson & Johnson's Net Income has seen a tremendous growth rate, increasing from $1300.00 to $20878.00 – an increase of 1506%. For next year, the 17.00 analysts predict earnings per share of $27222.61, which would mean an increase of 30.39%. Over the next nine years, the pros' prediction is Net Income of $29270.00, which would mean a 9-year growth forecast of 40.2%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
4
|
$195.71 | $287.21 | 16.24% | 24 |
| CERN Stock Forecast | Cerner | Hold |
6
|
$93.97 | $93.31 | 1.1% | 3 |
| BGNE Stock Forecast | BeiGene | Outperform |
0
|
$305.60 | $0.00 | 7.98% | 5 |
Johnson & Johnson EBITDA Forecast for 2022 - 2025 - 2030
In the past four years, Johnson & Johnson's EBITDA has significantly grown, increasing from $24539.00 to $32637.00 – a growth of 33%. The next year looks mildly promising for Johnson & Johnson, with analysts predicting EBITDA of $34274.43 – an increase of 5.02%. Over the next nine years, experts anticipate that JNJ's EBITDA will grow at a rate of 66.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight | Hold |
5
|
$90.19 | $88.52 | 10.88% | 9 |
| AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
4
|
93.92€ | 113.10€ | 15.52% | 13 |
| BIO Stock Forecast | Bio-Rad Laboratories | Outperform |
7
|
$503.49 | $701.33 | 39.03% | 2 |
Johnson & Johnson EBIT Forecast for 2022 - 2025 - 2030
In the last four years, Johnson & Johnson's EBIT has grown by 33.6%, from $18897.00 to $25247.00. For the next year, analysts are expecting EBIT to reach a reasonable $30914.86 – an increase of 22.45%. Over the next nine years, experts predict that EBIT will grow by 39.26%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| AFX Stock Forecast | Carl Zeiss Meditec | Hold |
4
|
118.25€ | 165.40€ | 43.34% | 1 |
| BBWI Stock Forecast | Bath & Body Works | Buy |
6
|
$42.94 | $81.26 | 90.96% | 6 |
| A090430 Stock Forecast | Amorepacific | Outperform |
2
|
₩150.50k | ₩269.69k | 32.89% | 16 |
Johnson & Johnson EPS Price Prediction Forecast for 2022 - 2025 - 2030
Johnson & Johnson's EPS has seen major growth over the last four years, jumping from $7.30 to $9.80 – an increase of 34.25%. In the next year, analysts predict that EPS will reach an unimpressive $10.26 – an increase of 4.69%. For the next nine years, the forecast is for EPS to grow by 32.65%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CLN Stock Forecast | Clariant | Hold |
2
|
CHF18.99 | CHF19.93 | 5.32% | 7 |
| 7747 Stock Forecast | Asahi Intecc | Outperform |
1
|
¥2.56k | ¥0.00 | 17.23% | 0 |
| ALKS Stock Forecast | Alkermes | Hold |
0
|
$25.19 | $0.00 | 13.14% | 8 |